Published in Diabetes Metab Syndr Obes on October 12, 2012
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential. Eur J Nutr (2014) 0.90
On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol (2014) 0.84
Update on the treatment of type 2 diabetes mellitus. World J Diabetes (2016) 0.79
Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart (2015) 0.78
The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol (2016) 0.77
Acarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and Attenuates the Incidence and Severity of Collagen-induced Arthritis in Mice. Sci Rep (2015) 0.76
Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes. J Diabetes Investig (2014) 0.75
Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study. Indian J Endocrinol Metab (2013) 0.75
Untapped diamonds for untamed diabetes: The α-glucosidase inhibitors. Indian J Endocrinol Metab (2014) 0.75
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet (2002) 9.48
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 9.16
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 8.47
Metformin. N Engl J Med (1996) 7.66
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA (2007) 6.40
Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation (2002) 6.26
Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med (2001) 6.15
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med (2007) 6.09
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology (2011) 4.99
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA (2010) 4.83
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA (2010) 4.45
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ (2011) 4.05
Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia (1999) 3.60
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J (2004) 2.96
Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes (1999) 2.77
Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol (1999) 2.75
Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care (2005) 2.71
A role for central nervous system PPAR-γ in the regulation of energy balance. Nat Med (2011) 2.34
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care (2011) 2.16
Thiazolidinediones and fractures in men and women. Arch Intern Med (2009) 1.98
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes (2010) 1.68
The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care (2010) 1.67
Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care (1998) 1.63
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord (2010) 1.60
Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med (2012) 1.57
The postprandial state and the risk of atherosclerosis. Diabet Med (1997) 1.47
Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation (1997) 1.45
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med (2008) 1.37
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care (2008) 1.34
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) Diabetes Care (1999) 1.32
Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke (2004) 1.30
Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation (2000) 1.27
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag (2008) 1.27
Intestinal disaccharidase activities in relation to age, race, and mucosal damage. Gastroenterology (1978) 1.25
Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion (1995) 1.23
Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab (2005) 1.21
Exenatide and acute pancreatitis. J Assoc Physicians India (2008) 1.18
Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol (1995) 1.09
Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res (1998) 1.08
Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol (2010) 1.08
Apparent digestibility of neutral detergent fiber in elderly and young adults. Am J Clin Nutr (1981) 1.05
Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest (2005) 1.03
Exenatide and rare adverse events. N Engl J Med (2008) 1.03
Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract (2001) 1.03
Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes (1996) 1.02
Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract (1999) 1.02
Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab (2007) 1.02
Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgrad Med J (2005) 1.01
Effect of metformin on patients with impaired glucose tolerance. Diabet Med (1999) 1.00
Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia (1996) 0.99
C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study. Diabet Med (2002) 0.97
Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus : a postmarketing surveillance study. Clin Drug Investig (2005) 0.95
Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res (1996) 0.94
Influence of acarbose on blood glucose and breath hydrogen after carbohydrate load with sucrose or starch. Arzneimittelforschung (2009) 0.94
Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia (1996) 0.94
Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study. Diabetes Care (2005) 0.91
Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients--an analysis of the DiaRegis registry. Cardiovasc Diabetol (2011) 0.91
The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complications (2011) 0.88
Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res (2004) 0.87
Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med (1995) 0.86
Pharmacokinetic-pharmacodynamic relationships of Acarbose. Clin Pharmacokinet (1996) 0.86
Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract (1998) 0.85
International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract (2011) 0.85
Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diabetes Obes Metab (2004) 0.84
The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies. Clin Ther (1998) 0.84
Adaptation of the small intestine to induced maldigestion in rats. Experimental pancreatic atrophy and acarbose feeding. Scand J Gastroenterol Suppl (1985) 0.83
European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol (1998) 0.83
Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. Pharmacotherapy (1999) 0.82
Acarbose: a review of US clinical experience. Clin Ther (1997) 0.82
Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. Clin Drug Investig (2007) 0.81
Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med (1999) 0.81
Digestive function and aging. Hum Nutr Clin Nutr (1983) 0.80
Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial. J Hypertens (2012) 0.80
Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance. Metabolism (2006) 0.80
The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes Nutr Metab (2002) 0.79
Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system. Curr Diabetes Rev (2009) 0.79
The effects of an alpha-glucoside hydrolase inhibitor on glycemia and the absorption of sucrose in man determined using a tracer method. Diabetes (1984) 0.79
The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics. Metabolism (1987) 0.78
Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab (1999) 0.78
Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose. J Gastroenterol (1997) 0.78
The effect of the timing and the administration of acarbose on postprandial hyperglycaemia. Diabet Med (1995) 0.78
Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridaemias. Br J Clin Pharmacol (1999) 0.77
Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis. Aliment Pharmacol Ther (1989) 0.77
Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C]acarbose to rats and dogs. Arzneimittelforschung (1989) 0.76
Metformin. Diabetes Care (1995) 0.76
Cardiovascular risk factors in newly diagnosed abnormal glucose tolerance: comparison of 1997 ADA and 1985 WHO criteria. Diabetologia (1999) 0.76
Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care (2002) 2.96
Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system. Curr Diabetes Rev (2009) 0.79
Modulation of circulating vasoactive peptides and extracellular matrix proteins are two novel mechanisms in the cardioprotective action of acarbose. Minerva Endocrinol (2016) 0.75